Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 4, 2014, Pages 341-353

  Abdel Raheem, Ihab T ^a   Khedr, Naglaa F ^b  

^a Damanhour University   (Egypt)

^b Tanta University   (Egypt)

Author keywords

BUN; MDA; Methotrexate; Montelukast; NF B; ROS; TNF

Indexed keywords

CREATININE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; METHOTREXATE; MONTELUKAST; MYELOPEROXIDASE; SCAVENGER; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ACETIC ACID DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEROXIDASE; PROTECTIVE AGENT; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY INJURY; KIDNEY PARENCHYMA; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; WISTAR RAT;

ACETATES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; GLUTATHIONE; KIDNEY; KIDNEY DISEASES; LEUKOTRIENE ANTAGONISTS; MALE; MALONDIALDEHYDE; METHOTREXATE; NF-KAPPA B; PEROXIDASE; PROTECTIVE AGENTS; QUINOLINES; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898670973     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0949-x     Document Type: Article

References (61)

1. Abraham P, Kolli VK, Rabi S (2010) Melatonin attenuates methotrexate-induced oxidative stress and renal damage in rats. Cell Biochem Funct 28:426-433
2. Alam MK, Sutradhar SR, Pandit H, Ahmed S, Bhattacharjee M, Miah AH et al (2012) Comparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritis. Mymensingh Med J 21:391-398
3. Asvadi I, Hajipour B, Asvadi A, Asl NA, Roshangar L, Khodadadi A (2011) Protective effect of pentoxyfilline in renal toxicity after methotrexate administration. Eur Rev Med Pharmacol Sci 15:1003-1009
4. Babiak RM, Campello AP, Carnieri EG, Oliveira MB (1998) Methotrexate: pentose cycle and oxidative stress. Cell Biochem Funct 16:283-293
5. Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW et al (1995) Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol 42:457-464
6. Beytur A, Ciftci O, Oguz F, Oguzturk H, Yilmaz F (2012a) Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats. Cancer Chemother Pharmacol 69:207-213
7. Beytur A, Köse E, Sarihan ME, Sapmaz HI, Dogan Z, Cetin A et al (2012b) Beneficial effects of montelukast against cisplatin-induced acute renal damage in rats. Ren Fail 34:343-349
8. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209
9. Caetano NN, Campello AP, Carnieri EG, Kluppel ML, Oliveira MB (1997) Effect of methotrexate (MTX) on NAD(P)+ dehydrogenases of HeLa cells: malic enzyme, 2-oxoglutarate and isocitrate dehydrogenases. Cell Biochem Funct 15:259-264
10. ÇakIr T, Özkan E, Dulundu E, Topaloǧlu Ü, Şehirli AÖ, Ercan F et al (2011) Caffeic acid phenethyl ester (CAPE) prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pharm Pharmacol 63:1566-1571
11. Cetinkaya A, Kurutas EB, Bulbuloglu E, Kantarceken B (2007) The effects of N-acetylcysteine on methotrexate-induced oxidative renal damage in rats. Nephrol Dial Transplant 22:284-285
12. Chan AJ, Rajakumar I (2013) High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Prac. doi: 10.1177/1078155213482602
13. Chen F, Castranova V, Shi X, Demers LM (1999) New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7-17
14. Coskun AK, Yigiter M, Oral A, Odabasoglu F, Halici Z, Mentes O et al (2011) The effects of montelukast on antioxidant enzymes and proinflammatory cytokines on the heart, liver, lungs, and kidneys in a rat model of cecal ligation and puncture-induced sepsis. Scientific World Journal 11:1341-1356
15. Cuciureanu M, Cǎruntu ID, Kuchar M, Nechifor M (2008) The influence of leukotriene receptors' antagonists on experimentally induced ulcer in rats. Rev Med Chir Soc Med Nat Iasi 112:750-756
16. Dengiz GO, Odabasoglu F, Halici Z, Cadirci E, Suleyman H (2007) Gastroprotective and antioxidant effects of montelukast on indomethacin-induced gastric ulcer in rats. J Pharmacol Sci 105:94-102
17. Devrim E, Cetin R, Kiliçoǧlu B, Ergüder BI, Avci A, Durak I (2005) Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail 27:771-773
18. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
19. El-Swefy S, Hassanen SI (2009) Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol 8:41-49
20. Fawcett JK, Scott JE (1960) A rapid and precise method for the determination of urea. J Clin Pathol 13:156-159
21. Granville DJ, Carthy CM, Jiang H, Levy JG, McManus BM, Matroule JY et al (2000) Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood 95:256-262
22. Helmy MM, El-Gowelli HM (2012) Montelukast abrogates rhabdomyolysis- induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production. Eur J Pharmacol 683:294-300
23. Hour TC, Chen J, Huang CY, Guan JY, Lu SH, Pu YS (2002) Curcumin enhances cytotoxicity of chemotherapeutic agents in prostate cancer cells by inducing p21(WAF1/CIP1) and C/EBPbeta expressions and suppressing NF-kappaB activation. Prostate 51:211-218
24. Huang L, Xie JN, Liang JP, Li YH, Zhou Y (2011) Sophoridine inhibits NF-kappaB signaling pathway activation in kidney tissue of endotoxemia mice. Yao Xue Xue Bao 46:1072-1077
25. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197
26. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ (2000) Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60:5334-5339
27. Izzedine H, Launay-Vacher V, Karie S, Caramella C, de Person F, Deray G (2005) Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 64:315-319
28. Kintzel PE (2001) Anticancer drug-induced kidney disorders. Drug Saf 24:19-38
29. Kolli VK, Abraham P, Isaac B, Selvakumar D (2009) Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 55:83-90
30. Kose E, Beytur A, Dogan Z, Ekincioglu Z, Vardi N, Cinar K et al (2012) The effects of montelukast against amikacin-induced acute renal damage. Eur Rev Med Pharmacol Sci 16:503-511
31. Marklund SL (1985) Superoxide dismutase isoenzymes in tissues and plasma from New Zealand black mice, nude mice and normal BALB/c mice. Mutat Res 148:129-134
32. May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND, May J, Carson KR, Butler S, Liu W, Bartlett NL, Wagner-Johnston ND (2013) High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma. doi: 10.3109/10428194.2013.840780
33. Mihara M, Uchiyama M (1978) Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86:271-278
34. Miyazaki J, Kawai K (2003) Prevention and management of nephrotoxicity from anti-cancer agents. Nihon Rinsho 61:973-977
35. Oktem F, Yilmaz HR, Ozguner F, Olgar S, Ayata A, Uzare E et al (2006) Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester. Toxicol Ind Health 22:241-247
36. Otunctemur A, Ozbek E, Cekmen M, Cakir SS, Dursun M, Polat EC et al (2013) Protective effect of montelukast which is cysteinyl-leukotriene receptor antagonist on gentamicin-induced nephrotoxicity and oxidative damage in rat kidney. Ren Fail 35:403-410
37. OzbakIş-Dengiz G, CadIrcI E, Yurdakan G (2013) Histopathologic evaluation of anti-ulcerogenic effect of montelukast in indomethacin-induced experimental ulcer model. Turk J Gastroenterol 24:88-92
38. Perez-Verdia A, Angulo F, Hardwicke FL, Nugent KM (2005) Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature. Pharmacotherapy 25:1271-1276
39. Peters-Golden M (2003) Do anti-leukotriene agents inhibit asthmatic inflammation. Clin Exp Allergy 33:721-724
40. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842
41. Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661
42. Sener G, Sehirli O, Cetinel S, Ercan F, Yüksel M, Gedik N et al (2005) Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast. Prostaglandins Leukot Essent Fatty Acids 73:453-462
43. Sener G, Sehirli O, Velioǧlu-Oǧünç A, Cetinel S, Gedik N, Caner M et al (2006a) Montelukast protects against renal ischemia/reperfusion injury in rats. Pharmacol Res 54:65-71
44. Sener G, Ekşioǧlu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N et al (2006b) L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 22:47-60
45. Slot C (1965) Plasma creatinine determination. A new and specific Jaffe reaction method. Scand J Clin Lab Invest 17:381-387
46. Stark AN, Jackson G, Carey PJ, Arfeen S, Proctor SJ (1989) Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 24:243-245
47. Suddek GM (2013) Montelukast ameliorates kidney function and urinary bladder sensitivity in experimentally induced renal dysfunction in rats. Fundam Clin Pharmacol 27:186-191
48. Tintinger GR, Feldman C, Theron AJ, Anderson R (2010) Montelukast: more than a cysteinyl leukotriene receptor antagonist. Scientific World Journal 10:2403-2413
49. Tuǧtepe H, Sener G, Cetinel S, Velioǧlu- Oǧünç A, Yeǧen BC (2007) Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist. Eur J Pharmacol 557:69-75
50. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem 272:31092-31099
51. Van't Land B, Blijlevens NM, Marteijn J, Timal S, Donnelly JP, de Witte TJ et al (2004) Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 18:276-284
52. Vardi N, Parlakpinar H, Ates B, Cetin A, Otlu A (2013) The protective effects of Prunus armeniaca L (apricot) against methotrexate-induced oxidative damage and apoptosis in rat kidney. J Physiol Biochem 69:371-381
53. Wang B, Peng L, Zhu L, Ren P (2007) Protective effect of total flavonoids from Spirodela polyrrhiza (L.) Schleid on human umbilical vein endothelial cell damage induced by hydrogen peroxide. Colloids Surf B Biointerfaces 60:36-40
54. Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16-25
55. Welch GN, Loscalzo J (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050
56. Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694-703
57. Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A et al (2010) Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 28:3979-3986
58. Williams JD, Czop JK, Austen KF (1984) Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. J Immunol 132:3034-3040
59. Wu Y, Zhou C, Tao J, Li S (2006) Montelukast prevents the decrease of interleukin-10 and inhibits NF-kappaB activation in inflammatory airway of asthmatic guinea pigs. Can J Physiol Pharmacol 84:531-537
60. Zeller JM, Buys CM, Gudewicz PW (1984) Effects of high-dose methotrexate on rat alveolar and inflammatory macrophage populations. Inflammation 8:231-239
61. Zheng L, Sinniah R, Hsu SI (2006) Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Hum Pathol 37:637-647